 The study aimed to increase diversity in local Los Angeles County NIH, sponsored Phase 3 SARS-CoV-2 vaccine clinical trials by forming a community consultant panel, CCP, which worked closely with local investigators to modify recruitment, outreach, and trial protocols. The panel provided critical insight on best practices for community trust building, clinical trial participation, and reliable information dissemination regarding COVID-19 vaccines. This resulted in majority minority participants, 55 percent to 78 percent, in each of the three vaccine clinical trials. Additionally, the panel was able to identify and address barriers such as childcare, requests for after-hours appointment availability, and mobile locations for trial visits. This article was authored by Yelba Castellan Lopez, Rafael Landovitz, Edgeron Techu, and others.